We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MAGN:NYSEMagnera Corporation Analysis

Data as of 2026-04-16 - not real-time

$10.60

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Magnera (MAGN) trades at $10.6, comfortably above its 20‑day SMA of $9.63 but below the 50‑day ($11.63) and 200‑day ($12.13) averages, indicating a short‑term price advantage yet a longer‑term bearish bias. The stock sits near the technical resistance of $10.89 and above the near‑term support of $8.71, while the RSI of 53.8 suggests neutral momentum and the MACD histogram turning positive signals a potential short‑term bounce. However, volume is on a decreasing trend and the 30‑day volatility is high at 52%, compounded by a beta of 1.62, reflecting pronounced price swings relative to the market.
Fundamentally, MAGN is heavily leveraged (debt‑to‑equity ≈ 192) and posted a negative profit margin of –4%, yet it generates positive operating and free cash flow and projects a forward EPS of $0.91. The DCF fair value of $64.04 and a target price of $14 imply a 32% upside from current levels, while the price‑to‑book of 0.37 underscores deep value relative to its book. Analyst consensus is a “hold” amid extreme market greed (Fear‑Greed Index ≈ 89), suggesting caution despite the attractive valuation metrics.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish longer‑term trend (price below SMA50/200)
  • Decreasing volume and high 30‑day volatility
  • Technical proximity to resistance at $10.89

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation upside (target $14, DCF $64)
  • Positive cash flow generation despite earnings loss
  • Forward EPS turning positive

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Deep discount to book value (P/B ≈ 0.37)
  • Revenue growth of ~13% YoY in a defensive consumer sector
  • Potential balance‑sheet improvement as cash offsets part of debt

Key Metrics & Analysis

Financial Health

Revenue Growth12.80%
Profit Margin-4.04%
P/E Ratio11.6
ROE-12.41%
ROA1.90%
Debt/Equity192.00
P/B Ratio0.4
Op. Cash Flow$163.0M
Free Cash Flow$172.1M

Technical Analysis

TrendBearish
RSI53.8
Support$8.71
Resistance$10.89
MA 20$9.63
MA 50$11.63
MA 200$12.13
MACDBullish
VolumeDecreasing
Fear & Greed Index88.98

Valuation

Fair Value$64.04
Target Price$14.00
Upside/Downside32.08%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.62
Volatility52.24%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.